Hypercholesterolemia Market Report 2026

Hypercholesterolemia Market Overview

• Hypercholesterolemia market size has reached to $18.61 billion in 2025 • Expected to grow to $35.59 billion in 2030 at a compound annual growth rate (CAGR) of 13.8% • Growth Driver: Increasing Cardiovascular Diseases Drives Market Growth • Market Trend: Innovative Approaches In Hypercholesterolemia Triple-Combination Drug Amrozet By Celltrion Pharm • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hypercholesterolemia Market?

Hypercholesterolemia refers to an abnormally high level of cholesterol in the blood, particularly low-density lipoprotein (LDL) cholesterol, which increases the risk of atherosclerosis and cardiovascular diseases such as heart attacks and strokes. It is often influenced by genetic factors, poor diet, lack of physical activity, and underlying health conditions like diabetes or hypothyroidism. The main types of hypercholesterolemia are genetic and acquired. Genetics refers to the study of genes, heredity, and the variation of inherited traits in living organisms, which play a crucial role in determining susceptibility to various conditions, including familial hypercholesterolemia. These are treated using various treatments, including statins, bile acid resins, niacin, PCSK9 inhibitors, cholesterol absorption inhibitors, fibric acid derivatives, and other treatments. The various routes of administration include oral and injectable. These are distributed through various distribution channels, such as hospital pharmacies, retail pharmacies, and other distribution channels, and are used by various end users, such as hospitals, specialty clinics, home healthcare, and other end users.

What Is The Hypercholesterolemia Market Growth Forecast?

The hypercholesterolemia market size is expected to see rapid growth in the next few years. It will grow to $35.59 billion in 2030 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to growing awareness of familial hypercholesterolemia, increasing adoption of biologic therapies, rising aging population, advancements in lipid profiling diagnostics, expanding preventive healthcare initiatives. Major trends in the forecast period include increasing adoption of pcsk9 inhibitors, growing emphasis on early screening and diagnosis, rising demand for combination lipid-lowering therapies, shift toward injectable long-acting treatments, expanding role of preventive cardiovascular care.

Global Hypercholesterolemia Market Segmentation

1) By Disease Type: Genetic, Acquired 2) By Treatment: Statins, Bile Acid Resins, Niacin, PCSK9 Inhibitors, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Other Treatments 3) By Route Of Administration: Oral, Injectable 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels 5) By End User: Hospitals, Specialty Clinics, Home Healthcare, Other End Users Subsegments: 1) By Genetic: Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia 2) By Acquired: Primary Hypercholesterolemia, Secondary Hypercholesterolemia

What Is The Driver Of The Hypercholesterolemia Market?

Increasing cardiovascular diseases is expected to propel the growth of the hypercholesterolemia market going forward. Cardiovascular diseases (CVDs) refer to a group of disorders that affect the heart and blood vessels. The increase in cardiovascular diseases is due to unhealthy diets, physical inactivity, rising obesity rates, chronic stress, aging populations, and the prevalence of conditions such as hypertension and diabetes. Hypercholesterolemia treatment supports cardiovascular disease patients by lowering LDL cholesterol levels, reducing arterial plaque buildup, improving blood flow, and decreasing the risk of heart attacks, strokes, and other cardiovascular complications. For instance, in October 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, each year, approximately 805,000 people in the United States experience a heart attack, of these, 605,000 are first-time incidents, while 200,000 occur in individuals with a history of previous heart attacks. Therefore, the increasing cardiovascular diseases are expected to drive the growth of the hypercholesterolemia industry.

Key Players In The Global Hypercholesterolemia Market

Major companies operating in the hypercholesterolemia market are Pfizer Inc., Merck & Co Inc., Abbvie Inc., Bayer AG, Sanofi S.A., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Amgen Inc., Viatris Inc., Aegerion Pharmaceuticals Inc., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Chiesi Farmaceutici S.p.A., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Limited, Ionis Pharmaceuticals Inc., NewAmsterdam Pharma N.V., HDL Therapeutics Inc.

Global Hypercholesterolemia Market Trends and Insights

Major companies operating in the hypercholesterolemia market are developing innovative products, such as a triple-combination drug, to enhance treatment efficacy and patient compliance. A triple-combination drug refers to a pharmaceutical formulation that combines three active ingredients into a single dosage form, such as a tablet or capsule. For instance, in February 2025, Celltrion Pharm, Inc., a South Korea-based pharmaceutical company, launched Amrozet Tablet, a hypertension-hyperlipidemia drug. This medication combines three active ingredients such as amlodipine, a calcium channel blocker for hypertension, rosuvastatin, a statin for lowering cholesterol and ezetimibe, which helps reduce cholesterol absorption in the intestines. The drug is available in four dosage combinations that include 5/5/10 mg, 5/10/10 mg, 10/5/10 mg, and 10/10/10 mg. It is indicated for hypertension and myocardial ischemia under amlodipine and primary hypercholesterolemia under the rosuvastatin-ezetimibe combination. It is also used to relieve chronic stable angina (chest pain) or vasospastic angina and to lower the risk of hospitalization for angina and heart surgery in patients with documented coronary artery disease.

What Are Latest Mergers And Acquisitions In The Hypercholesterolemia Market?

In August 2023, HDL Therapeutics, Inc., a US-based biotechnology company, merged with Swiftmerge Acquisition Corp. for an undisclosed amount. With this merger, HDL Therapeutics aims to enhance the commercialization of its FDA-approved Plasma Delipidation System (PDS-2) for treating patients with homozygous familial hypercholesterolemia (HoFH). Swiftmerge Acquisition Corporation is a US-based special purpose acquisition company (SPAC) that provides treatment for homozygous familial hypercholesterolemia (HoFH).

Regional Outlook

North America was the largest region in the hypercholesterolemia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hypercholesterolemia Market?

The hypercholesterolemia market consists of sales of omega-3 fatty acid supplements, atorvastatin, and simvastatin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hypercholesterolemia Market Report 2026?

The hypercholesterolemia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hypercholesterolemia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.